Results 51 to 60 of about 1,126 (138)

Spotlight on emicizumab in the management of hemophilia A: patient selection and special considerations

Journal of Blood Medicine, 2019
Koji Yada, Keiji NogamiDepartment of Pediatrics, Nara Medical University, Kashihara, Nara, JapanAbstract: Emicizumab is a factor (F)VIIIa-mimicking bispecific antibody recognizing FIXa and FX molecules.
Yada K, Nogami K
doaj  

Real‐World Experience With Emicizumab for Haemophilia A From the Physician Perspective in a Real‐World Clinical Setting

Haemophilia, EarlyView.
ABSTRACT Introduction Emicizumab is a bispecific antibody approved for prophylaxis in people with haemophilia A (PwHA). Aim To describe from the physician perspective the characteristics and treatment experiences of PwHA receiving emicizumab. Methods The Adelphi Real World Haemophilia Disease Specific Programme is a cross‐sectional, retrospective data ...
Michael Recht, Chris Blazos, Sophie Lai, Nathan Ball, Ella Morton, Lucy Lee, Juliana M. L. Biondo, Janet S. Lee   +7 more
wiley   +1 more source

Inhibitory hemophilia: contemporary treatment with emicizumab. Considerations for pediatric practice [PDF]

Introduction. This article provides an overview of current knowledge and global experience regarding the use of emicizumab, with a focus on its specific considerations in pediatric practice.
Agachi, Dorina, Țurea, Valentin, Eșanu, Galina   +2 more
core   +1 more source

NXT007 enhances in vitro coagulation potential in the coexistence of emicizumab in hemophilia A through distinct complex formation

Research and Practice in Thrombosis and Haemostasis
Background: NXT007 is a factor (F)VIIIa-mimetic bispecific antibody (BsAb) for hemophilia A (HA), engineered from emicizumab. It is designed to achieve non-hemophiliac levels of plasma coagulation potential and is currently under clinical development. In
Kazuki Yamaguchi, Kenta Haraya, Hikaru Koga, Kei Nishimura, Keito Inaba, Masaru Muraoka, Atsushi Muto, Takehisa Kitazawa   +7 more
doaj   +1 more source

Emicizumab in tolerized patients with hemophilia A with inhibitors: A single‐institution pediatric cohort assessing inhibitor status

Research and Practice in Thrombosis and Haemostasis, 2021
Background The majority of patients with hemophilia A with inhibitors who undergo immune tolerance induction (ITI) achieve successful tolerance and transition to factor VIII (FVIII) prophylaxis. A portion of these patients have switched to emicizumab for
Glaivy Batsuli, Amanda Greene, Shannon L. Meeks, Robert F. Sidonio Jr   +3 more
doaj   +1 more source

Changes in Hypertrophic Synovium Status in Adult Patients With Severe Hemophilia A Receiving Emicizumab Prophylaxis: The RESOLVE Study

Haemophilia, EarlyView.
ABSTRACT Background Evidence on the impact of emicizumab on joint health, particularly hypertrophic synovium (HS), remains limited. Objectives To evaluate changes in HS, using point‐of‐care ultrasound and clinical examination in People with Haemophilia (PwH) switching from replacement therapy to emicizumab.
Matteo Nicola Dario Di Minno, Erminia Baldacci, Ilenia Lorenza Calcaterra, Guido D'Errico, Cristina Santoro, Alessandra Strangio, Silvia Sorella, Marzia Leotta, Rita Carlotta Santoro   +8 more
wiley   +1 more source

Efficacy of emicizumab in patients with severe haemophilia A without factor VIII inhibitors in Germany: evaluation of real-life data documented by the smart medication eDiary

Therapeutic Advances in Hematology
Background: Systematically documented data on real-world use of emicizumab, a bispecific antibody factor (F)VIII mimetic, are still lacking in people with severe haemophilia A (PwSHA).
Carmen Escuriola Ettingshausen, Wolfgang Eberl, Hermann Eichler, Ronald Fischer, Christina Hart, Katharina Holstein, Ralf Knöfler, Jürgen Kreutz, Caspar David Kühnöl, Wolfgang A. Miesbach, Christian Pfrepper, Andreas Rösch, Ulrich J. Sachs, Karolin Trautmann-Grill, Wolfgang Mondorf   +14 more
doaj   +1 more source

Patient Perspectives in Haemophilia A: Unmet Needs of Individuals Receiving Factor and Non‐Factor Treatments

Haemophilia, EarlyView.
ABSTRACT Introduction There is limited qualitative published real‐world data on treatment patterns among people with severe haemophilia A (PwSHA), particularly those with unmet needs. Aim This qualitative study aimed to explore the impact of taking prophylactic extended half‐life factor VIII (EHL‐FVIII) or emicizumab on psychosocial and physical ...
Nana Kragh, Veruska Carboni, Duygu Bozkaya, Idaira Rodriguez‐Santana, Claudia Mighiu, Bethany Franks, Arnoud Plat, Randall Curtis   +7 more
wiley   +1 more source

Adoption of emicizumab (Hemlibra®) for hemophilia A in Europe: Data from the 2020 European Association for Haemophilia and Allied Disorders survey

, 2021
BACKGROUND: Emicizumab, a bispecific monoclonal antibody administered subcutaneously, mimicking the action of activated coagulation factor VIII, has been approved in Europe for use in patients with severe hemophilia of all ages.
Hermans C., Makris, Michael, Angelos Athanasopoulos, Athanasopoulos A., Fijnvandraat, Karin, Michael Makris, Peyvandi, Flora, Hermans, Cédric, Flora Peyvandi, Evelien Krumb, Ryan, Aislin, Cedric Hermans, Peyvandi F., Aislin Ryan, Krumb E., Krumb, Evelien, Karin Fijnvandraat, Fijnvandraat K., Makris M., Ryan A., Athanasopoulos, Angelos   +20 more
core   +1 more source

Perioperative Management in Persons With Haemophilia on Rebalancing Therapies: A Narrative Review

Haemophilia, EarlyView.
ABSTRACT Introduction Perioperative management in haemophilia often requires on‐demand use of clotting factor concentrates (CFC) and/or bypassing agents. Rebalancing agents (fitusiran, concizumab, marstacimab) offer a novel approach to prophylaxis by modulating endogenous anticoagulant pathways to restore haemostatic balance.
Amanda M. Henderson, Roy Khalife, Kelsey Uminski   +2 more
wiley   +1 more source